Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Vascular endothelial growth factor A (VEGFA) · developed by Merck &
MK-2010 is a bispecific antibody that binds PD-1 on T-cells and VEGF, blocking PD-1 activation by its ligands PD-L1 and PD-L2 and blocking VEGF binding to VEGFR. It is being studied in recurrent ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07793942 | Phase 2 | Malignant Neoplam | Recruiting | MRK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ovarian Cancer Recurrent
Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →